Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Neuroendocrine Tumors

• A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
• 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours
• A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
• DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
• Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
• Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
• Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
• Real-world Study on Adjuvant Octreotide Therapy in pNETs
• Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
• Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
• Multicenter Trial of ESK981 in Patients With Select Solid Tumors
• A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer
• Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
• Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors
• An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
• DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
• A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
• A Study of PM8002 Injection in Combination With Chemotherapy in Patients With NEN
• Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms
• Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors
• A Bioequivalence Study of Sunitinib Malate Capsules.
• Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial
• Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor
• Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
• Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
• Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
• Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
• Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
• A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3
• A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
• Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
• Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy
• Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
• A Safety Study of 212Pb-Pentixather Radioligand Therapy
• F-Tryptophan PET/CT in Human Cancers
• Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study
• Biomarker Identification of Radionuclide Therapy-induced Radiation Responses
• Study of RYZ101 Compared With SOC in Pts With Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
• 177Lu-DOTA-EB-TATE in Untreated (Naïve) Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
• A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
• Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
• Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
• A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
• Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)
• Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms
• Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)
• Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
• Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
• Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
• Lutathera and ASTX727 in Neuroendocrine Tumours
• Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC
• Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients
• Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
• A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
• Open-label Study of Surufatinib in Japanese Patients
• Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma
• 18F-MFBG PET/CT in the Evaluation of Neuroendocrine Malignancies
• PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
• A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
• Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
• Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
• Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
• Combination Immunotherapy in Rare Cancers Under InvesTigation
• Assessment of the Schema of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated Neuroendocrine Tumor
• Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) (MK-6482-015)
• Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
• Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients
• 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
• Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine Tumors
• A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
• A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
• 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
• Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
• Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
• Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
• Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
• Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
• Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
• Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
• Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
• Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
• 18F-DOPA II - PET Imaging Optimization
• Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors
• Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
• A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
• A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
• Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
• Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
• Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
• Open-Label Surufatinib in European Patients With NET
• Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors
• Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
• Telotristat With Lutathera in Neuroendocrine Tumors
• Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
• A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
• Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
• A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3
• Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
• Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
• An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours
• A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
• A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
• Cabozantinib in High Grade Neuroendocrine Neoplasms
• Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
• Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET
• 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
• Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 in Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors
• Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe
• Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
• Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
• 18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
• Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
• A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
• Cabozantinib and Nivolumab for Carcinoid Tumors
• Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer
• A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
• Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
• Octreotide LAR in the Induction of Immunologic Response in NENs Patients
• Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression
• Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
• Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
• Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
• Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
• 68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
• An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
• Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression
• Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
• Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
• Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
• Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type
• Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
• Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
• Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
• A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
• Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
• Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors
• DEBOXA for Inoperable NET Liver Metastases
• Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
• Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
• A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
• Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
• Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases
• Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
• A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
• Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue
• Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
• Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)
• Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases
• Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
• A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
• Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
• A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
• Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET
• A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3
• Optimizing the Interval Between Cycles of PRRT With 177lu-dotatate in sstr2 Positive Tumors
• AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With Metastatic Well Differentiated Neuroendocrine Neoplasm
• Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients
• Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
• Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
• Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
• 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
• Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
• A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
• Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor
• Avelumab in G2-3 NET
• PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
• Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
• PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2
• To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
• MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
• Entinostat Neuroendocrine (NE) Tumor
• Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
• A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor
• A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor
• Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
• Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
• A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
• Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
• Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
• Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET
• TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
• Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
• A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
• A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
• Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
• Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
• Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
• FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
• 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
• Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
• Phase 2 Study of ONC201 in Neuroendocrine Tumors
• Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
• 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
• Circulating Tumor Cells and Tumor DNA in HCC and NET
• Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroe
• Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
• A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
• PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
• A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
• Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
• Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
• Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
• SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors
• Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors
• Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
• The MetNET-2 Trial
• A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)
• A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
• Pasireotide Treatment for Neuroendocrine Tumor
• Personalized PRRT of Neuroendocrine Tumors
• Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy
• Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
• Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
• 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
• Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver
• Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib
• Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment
• EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
• Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
• A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver
• Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours
• Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
• Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
• Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
• Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors
• [68 Ga]-DOTANOC PET/CT in GEP-NETs
• Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
• Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
• Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
• Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
• Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
• RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
• Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors
• Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor
• Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
• Theranostics: 68GaDOTATOC and 90YDOTATOC
• Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
• 18F-FDOPA PET in Neuroendocrine Tumours
• Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
• Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
• A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
• Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
• Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
• 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
• Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study
• 68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial
• Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
• Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
• A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus
• Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
• Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
• A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
• The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
• A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine Tumors
• Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
• Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
• Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
• OPALINE : A Study Of Morbidity And Mortality At 2 Years
• Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
• Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrin Tumor (pNET)
• Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
• GA-68 DOTA-TOC of Somatostatin Positive Malignancies
• 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
• Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
• 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
• Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
• A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
• Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
• Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
• Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
• 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.
• Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
• Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
• Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
• Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
• 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
• Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
• A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
• 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
• Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
• Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
• Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
• 68-Ga-DOTATATE PET-CT Scan for Diagnosis and Staging of Neuroendocrine Tumors
• Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients
• Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
• Randomized Phase III of PRRT Versus Interferon
• Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor
• 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
• Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
• Somatuline Predictive Factors in Acromegaly and NET
• Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
• Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
• VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
• Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
• Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014
• Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors
• TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
• Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
• A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
• Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG
• Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
• Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
• 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours
• BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
• Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
• Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
• Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
• An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Adv
• Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
• A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
• Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
• A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
• Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
• Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
• Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
• Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
• Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
• A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors
• A Study of Axitinib in Advanced Carcinoid Tumors
• Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
• Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
• 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
• Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
• 89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors
• Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
• RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
• Pazopanib as Single Agent in Advanced NETs
• Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
• A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
• Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
• 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
• Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
• Study of Everolimus (RAD001) in Combination With Lenalidomide
• Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
• Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
• Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors
• Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
• Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
• Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
• Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
• Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
• A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
• Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
• Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
• 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
• AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
• High Dose Somatostatin Analogues in Neuroendocrine Tumors
• Study of Panobinostat in Patients With Neuroendocrine Tumors
• DOTA-TOC in Metastasized Neuroendocrine Tumors
• Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
• 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors
• A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
• Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
• Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
• Capecitabine and Temozolomide for Neuroendocrine Cancers
• RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
• Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
• A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
• Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
• Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
• Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
• RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
• Somatuline Autogel Preference and Health Economy Study
• Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
• Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
• Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
• Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
• Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
• Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors
• Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
• Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
• Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
• RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
• Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
• Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors
• Lithium for Low-Grade Neuroendocrine Tumors
• Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
• Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
• Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
• Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
• Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
• A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors
• A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
• AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
• Pemetrexed in Patients With Advanced Neuroendocrine Tumors
• Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
• Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
• Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
• Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
• A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
• Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
• [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
• Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
• Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
• Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
• Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
• Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors
• Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors
• Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
• Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
• Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
• Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
• Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
• Treatment With SU11248 in Patients With Neuroendocrine Tumors
• EPO906 in Carcinoid and Other Neuroendocrine Tumors
• High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
• Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
• Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
• PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
• Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
• Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
• Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
• Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
• Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors